Potent and uniform fetal hemoglobin induction via base editing [Cut & Run]
Genetic manipulations to increase fetal hemoglobin (HbF, a2?2) in postnatal red blood cells (RBCs) can alleviate ß-thalassemia and sickle cell disease. We compared five strategies in CD34+ hematopoietic stem and progenitor cells, using either Cas9 nuclease, which creates uncontrolled indel mixtures, or adenine base editors (ABE), which generate more precise nucleotide changes. The most potent modification was ABE generation of ?-globin (HBG1/HBG2) -175 A>G, which creates a promoter binding motif for the transcriptional activator TAL1. In erythroid colonies with >87.5% on-target edits, those with -175 A>G expressed 81?±?7% HbF, versus 17?±?11% in unedited controls. In comparison, HbF levels were lower and more variable in erythroid cells modified with either of two Cas9 nuclease strategies with similar editing efficiencies, being 32?±?19% when a BCL11A repressor binding motif in the ?-globin promoter was targeted and 52?±?13% when the +58 BCL11A erythroid enhancer was targeted. Contrary to currently accepted models of ?-globin regulation, HbF levels varied significantly with different Cas9 indels that disrupted the ?-globin promoter BCL11A binding motif. The -175 A>G base edit also induced HbF more potently than did the Cas9 nuclease approaches in RBCs generated after transplantation of modified normal or SCD patient CD34+ cells into mice. Our data suggest a strategy for potent, uniform induction of HbF and provide insights into ?-globin gene regulation. More generally, we demonstrate that diverse indels generated by Cas9 nuclease can cause unexpected variations in biological outcomes that can be circumvented by base editing, with important implications for therapeutic gene editing efforts. Overall design: CUT&RUN experiments were performed in HUDEP-2 cells base editor edited HBG promoter region